SCHEMBL5229997

SCHEMBL5229997

COC(=O)C1(Cc2ccccc2)CN(C(=O)OC(C)(C)C)CCC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.43
TACR1 P25103 1/20 0.43
TACR3 P29371 1/20 0.43
ACHE P22303 1/20 0.42
GPR119 Q8TDV5 2/20 0.41
P2RX3 P56373 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
USP30 Q70CQ3 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
SCD5 Q86SK9 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
CYP11B2 P19099 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
PDK4 Q16654 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230017 1.00 STS (0.43) STSTACR1TACR3ACHEGPR119
SCHEMBL5230008 1.00 STS (0.43) STSTACR1TACR3ACHEGPR119
SCHEMBL4479936 0.89 LMNA (0.42) STSACHEGPR119P2RX3KDM4E
SCHEMBL5230371 0.87 GPR119 (0.38) STSACHEGPR119P2RX3USP30
SCHEMBL5230373 0.86 GPR119 (0.41) STSACHEGPR119P2RX3USP30
SCHEMBL5225910 0.85 STS (0.40) STSTACR1TACR3ACHEGPR119
SCHEMBL5228662 0.85 STS (0.40) STSTACR1TACR3ACHEGPR119
SCHEMBL5228656 0.85 STS (0.40) STSTACR1TACR3ACHEGPR119
SCHEMBL5225914 0.85 STS (0.40) STSTACR1TACR3ACHEGPR119
SCHEMBL31163752 0.85 GRM5 (0.43) ACHEGPR119USP30CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106459147-B Serine derivatives as ghrelin receptor agonists 拉夸里亚创药株式会社 2021-08-06 CN disclosed
EP-3131916-B1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC (JP) 2018-11-14 EP disclosed
US-9873695-B2 Serine derivatives as ghrelin receptor agonists RAQUALIA PHARMA INC. (JP) 2018-01-23 US disclosed
US-9873695-B2 Serine derivatives as ghrelin receptor agonists RAQUALIA PHARMA INC. (JP) 2018-01-23 US disclosed
US-20170197961-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2017-07-13 US disclosed
EP-3131916-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RaQualia Pharma Inc (JP) 2017-02-22 EP disclosed
WO-2016021191-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2016-02-11 WO disclosed
EP-0869968-B1 GROWTH-HORMONE SECRETAGOGUES PFIZER (US) 2007-05-02 EP disclosed
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-20020002283-A1 Process for preparing growth hormone secretagogues RAQUALIA PHARMA INC. (JP) 2002-01-03 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6313140-B1 ADMINISTERING TO A HUMAN OR OTHER ANIMAL PYRAZOLOPYRIMIDINE DERIVATIVE FOR PROPHYLAXIS OR THERAPY OF DISEASE OR CONDITION WHICH MAY BE TREATED OR PREVENTED BY GROWTH HORMONE PFIZER INC. 2001-11-06 US disclosed
US-6306875-B1 ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. PFIZER INC. 2001-10-23 US disclosed
US-6278000-B1 INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR PFIZER INC. 2001-08-21 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed
US-6124264-A GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS PFIZER INC. (US) 2000-09-26 US disclosed
EP-1031575-A1 Process for preparing growth hormone secretagogues Pfizer Products Inc. (US) 2000-08-30 EP disclosed
US-6110932-A INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING PFIZER INC. (US) 2000-08-29 US disclosed
US-6107306-A OSTEOPOROSIS PFIZER INC. (US) 2000-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002283-A1 Process for preparing growth hormone secretagogues GHRHR, GHSR, PRLHR STS 548/4885TACR1 855/4885TACR3 2386/4885
US-20170197961-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS GHSR, GHRHR, GIPR STS 180/4885TACR1 95/4885TACR3 318/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR STS 2194/4885TACR1 175/4885TACR3 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.